Articles with keyword CT

• Prognostic significance of longitudinal evaluation on egfr mutant ctdna during tki treatment in nsclc

  F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rjsev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, N.H. Abduloeva, V.V. Egorenkov, V.M. Moiseyenko

  mutations, EGFR, tumor, ctDNA, therapy.

• Nature and perfusion dynamics of peritumoral ring enhancement of small (5-9 mm) and very small (less than 5 mm) hypovascular liver metastases: dynamic CT during hepatic arteriography data analysis

  P.V. Balakhnin, A.S. Shmelev, E.G. Shachinov, M.J. Tsikoridze, A.V. Pozdnyakov, D.E. Matsko, V.M. Moiseyenko

  peritumoral ring enhancement, blood supply of liver metastases, detection of liver metastases, dynamic CT, CT during hepatic arteriography

• Main aspects and result ’s treatment of primary mediastinal b-cell large lymphoma

  J.N. Vinogradova, V.V. Rjabchikova, A.I. Chumachenko, E.V. Karjagina, N.V. Medvedeva, A.S. Luchinin, N.V. Minaeva, T.V. Shnejder, M.M. Hodzhibekova,

  primary mediastinal B-cell large lymphoma, radiotherapy, PET/CT.

• Neuroradiology: evaluation of effectiveness of surgery and the combined therapy of gliomas

  T.N.Trofimova

  MRI, PET, CT, glioma, chemo-radiation therapy, perfusion, spectroscopy

• The significance of the dynamics of PET biomarkers in assessing the response to R-CHOP immunochemotherapy in patients with diffuse large B-cell lymphoma

  Y.N. Vinogradova, M.S. Tlostanova, A.A. Ivanova, M.I. Zelyanina, N.V. Ilyin

  18F-FDG PET/CT, DLBCL, tumor metabolic volume, tumor glycolytic volume, R-CHOP.

• Immuno-related adverse events of checkpoint inhibitors

  G.Yu. Kharkevich, K.V. Orlova

  immune-related adverse events, skin toxicity, colitis, hepatitis,anti-CTLA-4, anti-PD-1, hypophysitis, melanoma

• Biomarkers predicting the effect of immunotherapy: what you need to know in practice?

  A.M. Konstantinova

  immunotherapy, CTLA-4, PD-1, PD-L1, microsatellite instability, mutation burden, tumor-infiltrating lymphocytes, biomarkers, efficacy.

• Efficacy of immune checkpoints inhibitors in the treatment of solid tumors

  A.A. Rumyantsev, S.A. Tjulandin

  drug therapy, immunotherapy, CTLA-4, PD-1, PD-L1, check-points, programmed cell death protein, nivolumab, pembrolizumab, ipilimumab, atezolizumab, biomarkers, efficacy